1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Serbia Pharmaceuticals and Healthcare Report Q3 2016

Serbia Pharmaceuticals and Healthcare Report Q3 2016

  • June 2016
  • -
  • Business Monitor International
  • -
  • 78 pages

Includes 3 FREE quarterly updates

BMI View: Serbia will remain an unattractive market for multinational drugmakers in comparison to itsregional neighbours. Government cost-containment, via severe drug price cuts, and continued economicissues will dampen the country's growth outlook.Headline Expenditure ProjectionsPharmaceuticals: RSD91.42bn (USD840mn) in 2015 to RSD87.40bn (USD760mn) in 2016; -4.4% inlocal currency terms and -9.5% in US dollar terms. Forecast unchanged from Q216.Healthcare: RSD406.31bn (USD3.73bn) in 2015 to RSD416.04bn (USD3.62bn) in 2016; 2.4% in localcurrency terms and -3.1% in US dollar terms. Forecast revised upwards from Q216.

Table Of Contents

Serbia Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Serbia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Serbia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 24
OTC Medicine Market Forecast 25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 26
Pharmaceutical Trade Forecast 27
Table: Pharmaceutical Trade Data And Forecasts (Serbia 2014-2020) 28
Table: Pharmaceutical Trade Data And Forecasts local currency (Serbia 2014-2020) 29
Industry Risk/Reward Index 30
Central And Eastern Europe Risk/Reward Index - Q3 2016 30
Serbia Risk/Reward Index 36
Rewards 36
Risks 37
Regulatory Review 39
Intellectual Property Environment 40
Pricing Regime 44
Reimbursement Regime 46
Market Overview 48
Healthcare Sector 49
Table: Healthcare Resources (Serbia 2010-2015) 52
Table: Healthcare Personnel (Serbia 2010-2015) 52
Table: Healthcare Activity (Serbia 2010-2015) 53
Research and Development 53
Clinical Trials 54
Epidemiology 55
Competitive Landscape 59
Research-Based Industry 59
Table: Table: Multinational Market Activity 59
Generic Drugmakers 60
Pharmaceutical Distribution 60
Pharmaceutical Retail Sector 61
Company Profile 62
Hemofarm (Stada) 62
Galenika 65
Demographic Forecast 68
Table: Population Headline Indicators (Serbia 2005-2025) 69
Table: Population By Age Group (Serbia 2005-2025) 69
Table: Population By Age Group % (Serbia 2005-2025) 70
Glossary 72
Methodology 74
Pharmaceutical Expenditure Forecast Model 74
Healthcare Expenditure Forecast Model 74
Notes On Methodology 75
Risk/Reward Index Methodology 76
Index Overview 77
Table: Pharmaceutical Risk/Reward Index Indicators 77
Indicator Weightings 78

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.